melanotan 1

29 adults with erythropoietic or X-linked protoporphyria received afamelanotide implants at Massachusetts General Hospital from 2021-2022. Median time to phototoxic symptom onset increased from 12.5 minutes pre-treatment to 45 minutes during treatment. EPP-QoL scores improved by 29.4 points and PROMIS-57 social function, physical function improved while depression scores decreased significantly. No changes observed in protoporphyrin levels or liver function. Results demonstrate dramatic clinical benefit for light tolerance and quality of life despite lack of biochemical improvement.

Comprehensive review examining MC1R signaling effects beyond pigmentation. MC1R activation by α-MSH or agonists stimulates cAMP pathway leading to increased eumelanin synthesis which quenches reactive oxygen species and reduces UV-induced DNA damage. Activation simultaneously enhances DNA repair capacity and antioxidant enzyme activity in melanocytes. Loss-of-function MC1R variants disrupt these protective pathways, allowing pheomelanin synthesis which generates ROS/NOS and increases malignant transformation risk. Cumulative outcome of eumelanin synthesis plus enhanced repair/antioxidant capacity maintains genomic stability.

Comprehensive review of afamelanotide as first α-MSH analog synthesized in 1980 with higher activity and stability than natural hormone. MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair, and modulates inflammation. First human volunteer studies showed subcutaneous bioavailability with long-lasting pigmentation at 0.08-0.21 mg/kg doses. Neither MC1R variants nor fair skin reduced afamelanotide-induced pigmentation in two human trials. Controlled-release formulation optimizes dosing. Approved by EMA in 2014 for EPP. No late effects in 25-year follow-up or after 8 years continuous use. Immunogenic potential excluded.

55-patient multicenter randomized controlled trial comparing combination afamelanotide (16 mg implants) plus NB-UVB versus NB-UVB monotherapy for generalized vitiligo. Combination therapy achieved superior repigmentation at day 168 (48.64% vs 33.26%, P=0.04) particularly in skin phototypes IV-VI. Facial repigmentation onset was faster in combination group (median 41 vs 61 days, P=0.001). Upper extremity onset also faster (46 vs 69 days, P=0.003). Adverse events included nausea, abdominal pain, hyperpigmentation of normal skin. Combination therapy promotes melanoblast differentiation and accelerates eumelanogenesis induced by phototherapy.

Two multicenter randomized double-blind placebo-controlled phase 3 trials in EU (74 patients) and US (94 patients) testing 16 mg afamelanotide implants every 60 days. EU patients received 5 implants over 180 days, US patients received 3 over 270 days. Primary endpoint was duration of direct sun exposure between 10am-6pm without pain. Afamelanotide increased median painless sun exposure by 69.4 hours in EU trial (P<0.001) and 6.0 hours in US trial. Secondary endpoints showed improved quality of life and increased total light exposure. Acceptable safety profile with common adverse events being nausea, headache, and injection site reactions.

Post-authorization safety and efficacy cohort study of 117 EPP patients in routine clinical practice receiving afamelanotide. Time spent outside increased by 6.1 hours/week (95% CI 2.96-9.23, P<0.001) during treatment. EPP-QoL score improved by 14% (95% CI 4.53-23.50, P<0.001). Phototoxic reactions became less severe and painful. Treatment continuation rate was 98% (115/117). Treatment effects increased with duration and patient age showed positive interaction (older patients benefited more). Results suggest afamelanotide more effective in real-world practice than placebo-controlled trials, likely due to gradual behavioral adaptation to increased light tolerance.

77 Caucasian individuals investigated for afamelanotide (MELANOTAN/NDP-MSH) effects in presence of MC1R variant genotypes. Administration produced significant increase in melanin density (p<0.001) in treated versus placebo individuals. Critically, afamelanotide increased melanin density to GREATER extent in individuals carrying variant alleles (Val60Leu, Asp84Glu, Val92Met, Arg142His, Arg151Cys, Arg160Trp) compared to those with no variants. Demonstrates afamelanotide effectively increases skin melanin content in individuals with MC1R variants who are most in need of photoprotection, overcoming functional receptor deficiencies through higher binding affinity.

Pilot study of 4 patients with generalized vitiligo treated with NB-UVB three times weekly plus four monthly 16 mg afamelanotide implants starting in second month. All patients experienced follicular and confluent repigmentation within 2 days to 4 weeks after initial implant, progressing significantly throughout treatment. Afamelanotide induced faster and deeper repigmentation in each case. All patients developed diffuse hyperpigmentation. Combination therapy appears to promote melanoblast differentiation, proliferation, and eumelanogenesis, with afamelanotide providing direct α-MSH source to melanocortin receptor system potentially defective in vitiligo skin.

US clinical experience study where EPP patients receiving afamelanotide completed questionnaires assessing treatment benefits including return to normal activities, phototoxic reactions, and effect on patient confidence. Prior to treatment, 75% indicated EPP affected their lives "very much" or "a lot." This decreased to 11% after first implant and 0% after subsequent implants. Number of patients willing to venture outside increased with each implant. Demonstrates progressive improvement in disease burden and patient confidence as treatment continues, supporting real-world effectiveness beyond controlled trial endpoints.

Comprehensive review of afamelanotide mechanism and clinical applications. Afamelanotide differs from natural α-MSH by amino acid substitutions at positions 4 and 7, providing up to 1000× higher potency in animal models. Works independently of UV stimulation though UV amplifies response. In vitro and in vivo studies demonstrate enhanced DNA repair after UV damage in keratinocytes. MC1R activation stimulates eumelanin which acts as broadband photoprotectant, induces antioxidant enzymes, enhances repair mechanisms, and modulates inflammation. Review covers applications in EPP (primary indication), vitiligo, solar urticaria, and Hailey-Hailey disease.